Drug intelligence / Profile preview

MT-004

Development stage: Preclinical
Lead developer: Mitotherapeutix
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

MT-004 is a preclinical CAR-T cell therapy candidate developed by Mitotherapeutix. It targets CD8, acting as a modulator of the cluster of differentiation 8 (CD8) molecule. The primary therapeutic area under investigation for MT-004 is neoplasms (cancers). As of the latest available information, it has not yet entered clinical trials in humans and remains in preclinical development[8].

Targets

CD8A (CD8 alpha/beta Coreceptor)

Beyond the preview

Go deeper on MT-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MT-004.

Explore the full profile